https://www.selleckchem.com/products/myk-461.html novel target for APL treatment.Peripheral arterial disease (PAD) is the third leading cause of cardiovascular morbidity worldwide, after coronary artery disease and stroke. As endogenous regulators of gene expression, microRNAs (miRs) are implicated in the development and progression of various diseases, including types of cancer, autoimmune diseases and heart diseases. In the present study, the role of miR‑124‑3p in PAD was investigated. The reverse transcription‑quantitative PCR results indicated that the expression levels of miR‑124‑3p were significantly increased in the ischemic tissue of the hindlimb ischemia (HLI) model and in hypoxic human umbilical vein endothelial cells compared with the corresponding control groups. Proliferation, wound healing and tube formation assays demonstrated the inhibition of miR‑124‑3p on angiogenesis in vitro and the HLI model indicated the same function of miR‑124‑3p in vivo. A dual‑luciferase reporter revealed STAT3 as the target of miR‑124‑3p. The expression levels of miR‑124‑3p in human blood were negatively correlated with ankle‑brachial index, which is an index for the evaluation of the severity of PAD. Collectively, the present study indicated that miR‑124‑3p was a critical regulator of angiogenesis in PAD, and a potential diagnostic, prognostic and therapeutic target for PAD.Intestinal surface epithelial cells (IECs) have long been considered as an effective barrier for maintaining water and electrolyte balance, and are involved in the mechanism of nutrient absorption. When intestinal inflammation occurs, it is often accompanied by IEC malfunction. Berberine (BBR) is an isoquinoline alkaloid found in numerous types of medicinal plants, which has been clinically used in China to treat symptoms of gastrointestinal pathogenic bacterial infection, especially bacteria‑induced diarrhea and inflammation. In the present study, IEC‑18 rat intestinal epithelial cells were treated wi